ETHAN BROWN: Open Payments
NPI 1255115762 · OWENSBORO, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,192 in 117 payments from 15 companies in 2025. Trend: 2023 $106 · 2024 $1,830 · 2025 $2,192
Food & beverage: $2,192
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 50 | $666 |
| Janssen Biotech, Inc. | 14 | $388 |
| Gilead Sciences, Inc. | 9 | $211 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 9 | $197 |
| GENZYME CORPORATION | 5 | $147 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $126 |
| Madrigal Pharmaceuticals | 4 | $89 |
| PFIZER INC. | 4 | $83 |
| Lilly USA, LLC | 4 | $74 |
| Ardelyx, Inc. | 4 | $62 |
Products named: RINVOQ, TREMFYA, DUPIXENT, XIFAXAN, ENTYVIO, REZDIFFRA, SKYRIZI, OMVOH.
Industry payments across KY — which companies pay providers there.
